Amgen Inc.
AMGN
Below: live stock price for Amgen Inc. (AMGN), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Amgen Inc. (AMGN) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 31,500 people. Over the past year AMGN traded between 269.77 and 391.29 USD. Trailing P/E sits near 25.51 on a market cap of about 197.69B USD. It currently yields 2.75% in dividends.
- Prev close
- $371.58
- Volume (24h)
- $1.05B
- Market cap
- $197.69B
- Currency
- USD
Score
45/ 100 · Mixed
- Value27
- Quality83
- Momentum49
- Growth36
- Risk50
- Dividend44
- Liquidity26
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 368.725 +0.66%
- +20 bars
- 372.1112 +1.59%
- +60 bars
- 373.4295 +1.95%
- +120 bars
- 373.478 +1.96%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0246 USD.
Interpretation
Composite signals look mixed. Strength: quality with weakness: balance-sheet liquidity. Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value27/100
Value looks fragile — driven by P/E (25.51).
P/E:25.51P/B:21.51PEG:2.01 - Quality83/100
Quality looks strong — driven by ROE (101.32%).
ROE:101.32%ROA:8.35%Profit margin:20.96%Gross margin:71.44% - Momentum49/100
Momentum looks mixed — driven by 52w change (23.80%).
52w change:23.80% - Growth36/100
Growth looks weak — driven by Revenue growth (5.80%).
Revenue growth:5.80%Earnings growth:4.40% - Risk50/100
Risk looks mixed — driven by Debt / equity (623.75).
Beta:0.4Debt / equity:623.75Short interest:2.39% - Dividend44/100
Dividend looks weak — driven by Payout ratio (67.22%).
Dividend yield:2.75%Payout ratio:67.22% - Liquidity26/100
Liquidity looks fragile — driven by Current ratio (1.26).
Current ratio:1.26Quick ratio:0.85
Derived from public market data — informational, not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
- ResistanceFib +161.8% extension472.4164 USD+28.97% from current
- ResistanceFib +100% extension436.56 USD+19.18% from current
- ResistanceFib +61.8% extension414.3964 USD+13.13% from current
- ResistanceFib +27.2% extension394.3215 USD+7.65% from current
- Current366.29 USD
- SupportFib 23.6% retracement364.8473 USD-0.39% from current
- SupportFib 38.2% retracement356.3764 USD-2.71% from current
- SupportFib 50% midpoint349.53 USD-4.58% from current
- SupportFib 61.8% retracement342.6836 USD-6.44% from current
- SupportFib 78.6% retracement332.9363 USD-9.11% from current
- SupportFib −27.2% extension304.7385 USD-16.80% from current
- SupportFib −61.8% extension284.6636 USD-22.28% from current
- SupportFib −100% extension262.5 USD-28.34% from current
Financials
- 52w high
- $391.29
- 52w low
- $269.77
- 52w change
- 23.80%
- Day high
- $378.54
- Day low
- $361.74
- P/E (TTM)
- 25.51
- Forward P/E
- 15.62
- PEG
- 2.01
- Price / Book
- 21.51
- Beta (5Y)
- 0.4
- Enterprise value
- 242.97B
- EV / Revenue
- 6.53
- EV / EBITDA
- 14.36
- EPS (TTM)
- $14.36
- Forward EPS
- $23.45
- Dividend yield
- 2.75%
- Dividend rate
- $10.08
- Payout ratio
- 67.22%
- Revenue (TTM)
- 37.22B
- EBITDA
- 16.92B
- Free cash flow
- 7.44B
- Total cash
- 12.04B
- Total debt
- 57.32B
- Debt / Equity
- 623.75
- Current ratio
- 1.26
- Quick ratio
- 0.85
- Profit margin
- 20.96%
- Gross margin
- 71.44%
- Return on assets
- 8.35%
- Return on equity
- 101.32%
- Shares outstanding
- 539.71M
- Float
- 538.22M
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Analyst & Risk
- Beta (vs S&P 500)
- 0.4
- very stable
- 52-week change
- 23.80%
- Short % of float
- 2.39%
- Short ratio (days)
- 4.09
- Debt / Equity
- 623.75
- very high leverage
- Current ratio
- 1.26
- Quick ratio
- 0.85
- ROE
- 101.32%
- ROA
- 8.35%
- PEG ratio
- 2.01
- richly valued
- EV / Revenue
- 6.53
- EV / EBITDA
- 14.36
- Revenue growth
- 5.80%
- Earnings growth
- 4.40%
- EBITDA
- 16.92B
- Free cash flow
- 7.44B
- Total cash
- 12.04B
- Total debt
- 57.32B
- Insider holdings
- 0.22%
- Institutional
- 86.52%
Recent rating changes
- 2026-07-13UBSBuy → Buymain
- 2026-07-13GuggenheimNeutral → Neutralmain
- 2026-07-08Morgan StanleyEqual-Weight → Equal-Weightmain
- 2026-07-07Truist SecuritiesHold → Holdmain
- 2026-07-06Cantor FitzgeraldNeutral → Neutralreit
- 2026-06-16MizuhoNeutral → Neutralmain
- 2026-06-10Morgan StanleyEqual-Weight → Equal-Weightmain
- 2026-05-14Piper SandlerOverweight → Overweightmain
Financial documents
- Annual report of employee stock purchase11-K2026-06-11
- Corporate Changes & Voting Matters8-K2026-05-20
- Corporate Changes & Voting Matters8-K2026-05-19
- Periodic Financial Reports10-Q2026-05-01
- Corporate Changes & Voting Matters8-K2026-04-30
- Corporate Changes & Voting Matters8-K2026-04-22
- Proxy StatementsDEFA14A2026-04-21
- Proxy StatementsDEFA14A2026-04-15
- Proxy StatementsDEF 14A2026-04-07
- Annual Report to ShareholdersARS2026-03-31
- Corporate Changes & Voting Matters8-K2026-02-19
- Periodic Financial Reports10-K2026-02-13
Recent news
- Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?Motley Fool2h ago
- What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.Barrons.com3h ago
- IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?Motley Fool22h ago
- IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?Motley Fool1d ago
- The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?24/7 Wall St.2d ago
- Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?Zacks3d ago
- MRK Stock Jumps on FDA Nod for Cholesterol-Lowering PillZacks2d ago
- Seagate Stock And The Bet On A Denser FutureTrefis2d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,473 USD-4.30%
- 7203.TToyota Motor Corporation2,899.5 USD-0.33%
- 9984.TSoftBank Group Corp.5,424 USD-9.01%
- 6758.TSony Group Corporation3,470 USD+0.93%
- 6861.TKeyence Corporation70,880 USD-4.28%
- NVDANVIDIA Corporation202.81 USD-2.21%
- AAPLApple Inc.333.74 USD+0.14%
- 0700.HKTencent Holdings Limited477.8 USD+3.51%
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.